Appetite-suppressant drugs and valvular heart disease

New England Journal of Medicine

Volumn 340, Issue 6, 1999, Pages 477-478

  Shapiro, Samuel ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE;

CHEMICALLY INDUCED DISORDER; CONFIDENCE INTERVAL; DOSE RESPONSE; HUMAN; LETTER; METHODOLOGY; PREVALENCE; RISK; VALVULAR HEART DISEASE; OBESITY; PATHOPHYSIOLOGY; WEIGHT REDUCTION; EPIDEMIOLOGY;

APPETITE DEPRESSANTS; CONFIDENCE INTERVALS; DEXFENFLURAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART VALVE DISEASES; HUMANS; PREVALENCE; RESEARCH DESIGN; RISK; OBESITY; WEIGHT LOSS; BIAS (EPIDEMIOLOGY); FENFLURAMINE; ODDS RATIO; PHENTERMINE;

EID: 0033545275     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713-8.
2. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997;46:1061-6.
3. Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT. Pulmonary hypertension and fenfluramine. BMJ 1981;283:881-3.
4. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993;70:537-41.